{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T13:35:16Z","timestamp":1793367316170,"version":"4.5.0"},"reference-count":22,"publisher":"Elsevier","isbn-type":[{"value":"9780443235917","type":"print"}],"license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024]]},"DOI":"10.1016\/bs.irn.2024.04.014","type":"book-chapter","created":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T07:23:33Z","timestamp":1720077813000},"page":"121-134","source":"Crossref","is-referenced-by-count":9,"title":["Cannabidiol and Alzheimer\u2019s disease"],"prefix":"10.1016","member":"78","reference":[{"key":"10.1016\/bs.irn.2024.04.014_bib1","unstructured":"Aisen, P. (2022). Life\u2019s end benefits of cannabidiol and tetrahydrocannabinol (LiBBY). https:\/\/clinicaltrials.gov\/study\/NCT05644262."},{"key":"10.1016\/bs.irn.2024.04.014_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.brainres.2020.147135","article-title":"Endocannabinoid system alterations in Alzheimer\u2019s disease: a systematic review of human studies","volume":"1749","author":"Berry","year":"2020","journal-title":"Brain Research"},{"issue":"4","key":"10.1016\/bs.irn.2024.04.014_bib3","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.3233\/JAD-140921","article-title":"Long-term cannabidiol treatment prevents the development of social recognition memory deficits in Alzheimer\u2019s disease transgenic mice","volume":"42","author":"Cheng","year":"2014","journal-title":"Journal of Alzheimer\u2019s Disease"},{"key":"10.1016\/bs.irn.2024.04.014_bib4","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1101452","article-title":"Advances in Alzheimer\u2019s disease\u2019s pharmacological treatment","volume":"14","author":"Conti Filho","year":"2023","journal-title":"Frontiers in Pharmacology"},{"issue":"1-2","key":"10.1016\/bs.irn.2024.04.014_bib5","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.neulet.2006.01.047","article-title":"Cannabidiol inhibits inducible nitric oxide synthase protein expression and nitric oxide production in beta-amyloid stimulated PC12 neurons through p38 MAP kinase and NF-kappaB involvement","volume":"399","author":"Esposito","year":"2006","journal-title":"Neuroscience Letters"},{"issue":"8","key":"10.1016\/bs.irn.2024.04.014_bib6","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1038\/sj.bjp.0707337","article-title":"Cannabidiol in vivo blunts beta-amyloid induced neuroinflammation by suppressing IL-1beta and iNOS expression","volume":"151","author":"Esposito","year":"2007","journal-title":"British Journal of Pharmacology"},{"issue":"12","key":"10.1016\/bs.irn.2024.04.014_bib900","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0028668","article-title":"Cannabidiol reduces A\u03b2-induced neuroinflammation and promotes hippocampal neurogenesis through PPAR\u03b3 involvement","volume":"6","author":"Esposito","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/bs.irn.2024.04.014_bib7","unstructured":"Gruber, S. (2021).\u00a0Open-label trial of a cannabidiol solution for the treatment of behavioral symptoms in older adults with Alzheimer\u2019s dementia. https:\/\/clinicaltrials.gov\/study\/NCT04075435."},{"issue":"6","key":"10.1016\/bs.irn.2024.04.014_bib8","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1046\/j.1471-4159.2001.00542.x","article-title":"Anandamide, but not 2\u2010arachidonoylglycerol, accumulates during in vivo neurodegeneration","volume":"78","author":"Hansen","year":"2001","journal-title":"Journal of Neurochemistry"},{"issue":"3","key":"10.1016\/bs.irn.2024.04.014_bib9","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s11064-018-2513-z","article-title":"Cannabidiol reverses deficits in hippocampal LTP in a model of Alzheimer\u2019s disease","volume":"44","author":"Hughes","year":"2019","journal-title":"Neurochemical Research"},{"issue":"4","key":"10.1016\/bs.irn.2024.04.014_bib10","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA research framework: Toward a biological definition of Alzheimer\u2019s disease","volume":"14","author":"Jack","year":"2018","journal-title":"Alzheimer\u2019s & Dementia"},{"issue":"1","key":"10.1016\/bs.irn.2024.04.014_bib11","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s41572-021-00269-y","article-title":"Alzheimer disease","volume":"7","author":"Knopman","year":"2021","journal-title":"Nature Reviews Disease Primers"},{"issue":"22","key":"10.1016\/bs.irn.2024.04.014_bib12","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1212\/WNL.0000000000007583","article-title":"A brief history of \u201cAlzheimer disease\u201d multiple meanings separated by a common name","volume":"92","author":"Knopman","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/bs.irn.2024.04.014_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctim.2021.102660","article-title":"Attitudes, beliefs, and changing trends of cannabidiol (CBD) oil use among caregivers of individuals with Alzheimer\u2019s disease","volume":"57","author":"Leszko","year":"2021","journal-title":"Complementary Therapies in Medicine"},{"issue":"6","key":"10.1016\/bs.irn.2024.04.014_bib14","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1124\/mol.111.071290","article-title":"Cannabidiol and other cannabinoids reduce microglial activation in vitro and in vivo: Relevance to Alzheimer\u2019s disease","volume":"79","author":"Mart\u00edn-Moreno","year":"2011","journal-title":"Molecular Pharmacology"},{"key":"10.1016\/bs.irn.2024.04.014_bib15","unstructured":"Mueller, R. (2023).\u00a0CBD for individuals at risk for Alzheimer\u2019s disease. https:\/\/clinicaltrials.gov\/study\/NCT05822362."},{"key":"10.1016\/bs.irn.2024.04.014_bib16","unstructured":"Okhravi, H. (2021). Effects of THC-free CBD oil on agitation in patients with Alzheimer\u2019s disease clinical trials. https:\/\/clinicaltrials.gov\/study\/NCT04436081."},{"key":"10.1016\/bs.irn.2024.04.014_bib17","author":"Organization","year":"2021","journal-title":"Global status report on the public health response to dementia"},{"issue":"3","key":"10.1016\/bs.irn.2024.04.014_bib18","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.neurobiolaging.2012.06.005","article-title":"CB2 receptor and amyloid pathology in frontal cortex of Alzheimer\u2019s disease patients","volume":"34","author":"Solas","year":"2013","journal-title":"Neurobiology of Aging"},{"issue":"2","key":"10.1016\/bs.irn.2024.04.014_bib19","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s40120-022-00338-8","article-title":"Alzheimer\u2019s disease: Epidemiology and clinical progression","volume":"11","author":"Tahami Monfared","year":"2022","journal-title":"Neurology and Therapy"},{"issue":"3","key":"10.1016\/bs.irn.2024.04.014_bib20","doi-asserted-by":"crossref","first-page":"937","DOI":"10.3233\/JAD-191242","article-title":"Chronic treatment with 50 mg\/kg cannabidiol improves cognition and moderately reduces A\u03b2 40 levels in 12-month-old male A\u03b2PP swe\/PS1\u0394E9 transgenic mice","volume":"74","author":"Watt","year":"2020","journal-title":"Journal of Alzheimer\u2019s Disease"},{"issue":"3","key":"10.1016\/bs.irn.2024.04.014_bib21","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/0306-4522(94)90511-8","article-title":"Cannabinoid receptor binding and messenger RNA expression in human brain: An in vitro receptor autoradiography and in situ hybridization histochemistry study of normal aged and Alzheimer\u2019s brains","volume":"63","author":"Westlake","year":"1994","journal-title":"Neuroscience"}],"container-title":["International Review of Neurobiology","Cannabidiol in Neurology and Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0074774224000667?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0074774224000667?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T15:50:32Z","timestamp":1754409032000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0074774224000667"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"ISBN":["9780443235917"],"references-count":22,"URL":"https:\/\/doi.org\/10.1016\/bs.irn.2024.04.014","relation":{},"ISSN":["0074-7742"],"issn-type":[{"value":"0074-7742","type":"print"}],"subject":[],"published":{"date-parts":[[2024]]}}}